EMA Adopts a Positive Opinion for Biosimilar Denosumab By Ogkologos - May 28, 2025 599 0 Facebook Twitter Google+ Pinterest WhatsApp Jubereq is a biosimilar of Xgeva, which was authorised in the EU in 2011 Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Time to take on 9 new Cancer Grand Challenges March 8, 2023 Appendix Cancers Are Genetically Distinct from Other Gastrointestinal Cancers, Study Shows September 12, 2018 Cancer-impacted mother becomes Times Square billboard to help child come across... July 21, 2023 Virtual Reality Found to Benefit Cancer Patients’ Mental Health October 15, 2021 Load more HOT NEWS Woman Diagnosed with Cancer a Week After Her Honeymoon Helps Others... Interpreted cancer awareness workshops: talking about cancer with South-Asian communities How to Get Started With Exercising at Home During Cancer EMA Recommends Granting a Marketing Authorisation for Germanium (68Ge) chloride /...
